ClinicalTrials.gg
RecruitingNCT06900829#aware hivUpdated Mar 12, 2026

#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

An interventional study of HIV team implementation in HIV Infection, HIV and Stigma, sponsored by Casper Rokx. Recruiting at 28 sites in 10 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Casper Rokx · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in HIV Infections with a site in Netherlands — 6 open to participants now, 10 under way, 2 of them phase 3. HIV Infections · Netherlands.

Planned enrollment
Largest of 74
5,200 · median 206
Started
2025
with 1 other
No phase
3 of 86
1 open now
Registered
84th of 86
by date

Among the 86 studies in HIV Infections with a site in Netherlands, this one has the largest planned enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 with no phase, and was the 84th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

6 of the 86 studies in HIV Infections with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in HIV Infections with a site in Netherlands, or all of them as a file.
02

Study summary

The #aware.hiv Europe study is a real-world, multicenter, stepped-wedge cluster randomized, effectiveness-implementation trial designed to evaluate whether the introduction of dedicated HIV teams in hospitals can improve HIV testing rates among patients presenting with HIV indicator conditions across ten European countries.

Study Design:

The study employs a stepped-wedge design, whereby clusters of hospitals transition sequentially from a control phase (routine care) to an intervention phase. All patient data are collected retrospectively from routine care, while prospective data are gathered at the healthcare professional level. The project spans four years and involves hospitals from the Netherlands, Belgium, United Kingdom, Germany, Spain, France, Italy, Romania, Poland, and Ukraine. This design allows for comparison of HIV testing rates and related outcomes before and after the implementation across different settings and time points.

Intervention:

The core intervention involves the establishment of hospital-based HIV teams. Each team is led by an HIV specialist and supported by nurses and data collectors. Their responsibilities include:

Identification and Surveillance: Screening routine electronic health records for HIV indicator conditions using predefined ICD-10 codes and verifying cases that warrant HIV testing.

Audit \& Feedback: Providing targeted recommendations to treating physicians when an HIV test is indicated but has not been performed, thereby prompting action.

Education \& Training: Delivering training sessions to healthcare professionals to improve their knowledge and attitudes towards HIV testing, prevention, and care.

Enabling Environment: Implementing digital solutions and other support mechanisms to streamline testing processes, reduce stigma, and enhance overall guideline adherence.

Linkage to prevention: Improving linkage to the locally available preventive services.

The intervention is intended to integrate seamlessly into routine hospital care, thereby reinforcing existing guidelines while addressing the current diagnostic testing gap.

Endpoints and Outcome Measures:

Primary Endpoint:

The change in HIV testing rate among patients diagnosed with HIV indicator conditions before and after the implementation of HIV teams.

Key Secondary Endpoints:

The change in the incidence of new HIV diagnoses among patients with HIV indicator conditions.

Variations in HIV testing rates across different countries, medical specialties, and types of indicator conditions, as well as over time.

Assessment of the cascade of HIV diagnosis, including the proportion of patients identified with an indicator condition, the offer and acceptance of HIV testing, and documented reasons for non-testing.

Evaluation of the cascade of HIV care and prevention, including linkage to HIV care, achievement of viral suppression, and referral and uptake of preventive services.

Changes in healthcare professionals' knowledge, attitudes, and levels of stigma towards HIV.

Implementation outcomes such as fidelity of HIV team activities, resource utilization, cost-effectiveness, and sustainability of the intervention.

Analysis of contextual factors, barriers, and facilitators impacting the implementation process, using established frameworks like CFIR and RE-AIM.

Impact:

By introducing HIV teams and systematically monitoring their effect on HIV testing practices, the study aims to enhance early HIV diagnosis and improve patient outcomes. The findings will contribute to evidence-based guidelines and may promote the adoption of similar interventions across European healthcare settings, ultimately reducing HIV-associated morbidity, mortality, and transmission rates.

This project not only addresses a critical diagnostic gap in HIV care but also provides valuable insights into the effective implementation of complex interventions in routine clinical practice.

03

Conditions studied

  • HIV Infection
  • HIV
  • Stigma
  • Education
  • Prevention of Infection With HIV-1
  • Electronic Health Records

Keywords

  • hiv
  • stigma
  • linkage to care
  • linkage to prevention
  • electronic prompts
  • behavioural intervention
  • ICD-10 code based
  • audit and feedback
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Since this study involves screening individuals presenting to a specific hospital through a hospital-wide intervention, the inclusion and exclusion criteria are established at the hospital level.

Inclusion criteria

Inclusion Criteria:

  1. Standard of care: testing for HIV indicator conditions should be part of routine care in the country, and any prevailing guidelines on HIV testing and prevention policies can be integrated.
  2. Management approval: Hospital management must be willing to allocate resources and provide authorization for the proposed activities, including Surveillance, Audit \& Feedback, Education \& Training, Linkage to Prevention, and fostering an Enabling Environment, including stigma reduction.
  3. Resources: Assembling an HIV team led by a local HIV expert should be viable considering the available human resources.
  4. Data collection: There should be an IT specialist and IT infrastructure capable of flagging a pre-defined set of HIV indicator conditions and monitoring the project's implementation effects with feedback loops to healthcare professionals.
  5. Quality assurance: Continuous linkage for care and access to antiretroviral therapy must be assured.
  6. Ethics and Regulatory Compliance: Provision for ethical and regulatory compliance is necessary.

Exclusion criteria

Exclusion Criteria:

Any hospital that does not meet the inclusion criteria will be excluded from participation. We will not use data of patients who have objected against the use of their data for research.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5,200 participants (estimated)

Study arms

  • Experimental
    hiv team implemented

    A local hiv team will be implemented in a certain hospital. This will result in different activities, with a focus on: * audit and feedback (reminding health care professionals to test for hiv) * stigma reduction (raising awareness on existing hiv stigma towards hiv) * education (increasing knowledge on hiv among health care professionals) * linkage to prevention and care (improving pathways for hiv care and prevention)

    Behavioral: HIV team implementation

Interventions

  • BehavioralHIV team implementation

    A local hiv team will be implemented in a certain hospital. This will result in different activities, with a focus on: * audit and feedback (reminding health care professionals to test for hiv) * stigma reduction (raising awareness on existing hiv stigma towards hiv) * education (increasing knowledge on hiv among health care professionals) * linkage to prevention and care (improving pathways for hiv care and prevention)

06

What researchers measure

Primary outcomes

  1. HIV testing rate in patients with HIV indicator conditions

    Proportion of patients diagnosed with an HIV indicator condition who receive an HIV test, compared between the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

Secondary outcomes

  1. HIV incidence in patients with HIV indicator conditions

    Number of newly diagnosed HIV infections among patients with an HIV indicator condition, compared between the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  2. Subgroup analysis 1: HIV testing rate by country and region

    Difference in HIV testing rate within and between countries, as well as between geographic regions (West: Netherlands, Belgium, UK, Germany; South: France, Italy, Spain; East: Poland, Romania, Ukraine), comparing the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  3. Subgroup analysis 2: HIV testing rate by HIV indicator condition

    Difference in HIV testing rate across different HIV indicator conditions, comparing the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  4. Subgroup analysis 3: HIV testing rate by medical specialty

    Difference in HIV testing rate across medical specialties, comparing the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  5. Subgroup analysis 4: HIV testing rate over time

    Change in HIV testing rate over time, comparing the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  6. Cascade 1: The cascade of HIV diagnosis

    Proportion of patients with a confirmed HIV indicator condition (focus population) who were offered an HIV test (reach) and who accepted testing (uptake), compared between the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  7. Cascade 1b: The cascade of HIV diagnosis - reasons for not testing for HIV

    Qualitative analysis of documented reasons why patients with an HIV indicator condition did not receive an HIV test. Reasons will be classified according to predefined categories used in the study database: No reason registered (1) Patient was not seen again (2) Advice to the general practitioner or public health to test (3) No perceived indication or risk factors (4) Alternative diagnosis/explanation (5) No recommendation in local protocol (6) Patient refused (7) Shared decision-making not to test (8) Lack of time or opportunity (9) Planned but not performed (10) Already tested (confirmed) (11) Already tested (not confirmed or inadequate according to the SOP) (12) Palliative care or patient deceased during follow-up (13) Other (14)

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  8. Cascade 1c: The cascade of HIV diagnosis - descriptions of existing consent procedures in different hospital sites

    Qualitative description of the consent procedures in place for HIV testing across different hospital sites. This includes: The types of consent procedures in use, such as verbal or written consent. National or institutional guidelines or local standard procedures that shape consent practices. Data will be collected per site to document existing practices without assessing implementation or adherence.

    Time frame: Description of consent procedures as documented during the 1-year implementation phase across different hospital sites.

  9. Cascade 2: The cascade of HIV care

    Proportion of patients with a confirmed HIV indicator condition who were newly diagnosed with HIV (focus population) and subsequently linked or re-linked to routine HIV care (reach), with viral suppression as an indicator of successful engagement in care (uptake), compared between the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  10. Cascade 3: The cascade of HIV prevention

    Proportion of patients with a confirmed HIV indicator condition who met the eligibility criteria for HIV prevention (focus population), were appropriately referred to prevention services (reach), and engaged in prevention interventions (uptake), compared between the control and implementation phases.

    Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.

  11. HIV stigma indicators among health care professionals

    Descriptive assessment of self-reported HIV stigma among licensed healthcare professionals, including physicians, nurse practitioners, and physician assistants, before and after implementation. Stigma will be measured using a validated questionnaire developed by the Health Policy Project and USAID, and adapted from the ECDC survey published in Annex 1 of the report: "HIV stigma in the healthcare setting. Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia 2024." The survey includes self-reported responses on multiple dimensions of HIV stigma, expressed as percentages of participants reporting: 1. Fear of HIV infection 2. Institutional facilitators and barriers 3. Negative attitudes towards people with HIV 4. Observed stigma in clinical settings. This is a descriptive outcome measure, reporting the proportion of participants endorsing each stigma-related item before and after the intervention.

    Time frame: Assessed at baseline (before implementation) and at 12 months (after 1 year of implementation).

  12. Implementation science 1: Assessment of key barriers and facilitators over time (CFIR)

    Description: Descriptive assessment of perceived barriers and facilitators to implementing and sustaining the HIV team intervention in hospital settings. Barriers and facilitators will be assessed based on a structured survey, capturing key constructs from the Consolidated Framework for Implementation Research (CFIR): Intervention characteristics, Outer setting, Inner setting, Characteristics of individuals and the Implementation process. Survey items will be derived from a systematic review of barriers and facilitators to HIV indicator condition-based testing. The review will be published separately. Data will be collected via an online survey in Castor, administered to the HIV team lead at each participating site

    Time frame: Every 3 months during the implementation phase (first year). Every 6 months during the continuation phase (up to 3 years post-implementation).

  13. Implementation science 2: Reach: Proportion of patients benefiting from HIV team-supported testing

    Proportion of patients with HIV indicator conditions who received an HIV test with direct (= feedback) or indirect (= other implementation strategies) involvement of the HIV team, stratified by: * Country, hospital, and specialty to assess variation in reach * Equity analysis: evaluating differences in testing uptake by age and sex

    Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).

  14. Implementation science 3a: Effectiveness: Impact on HIV diagnosis rate

    Proportion of individuals who test HIV-positive among: All individuals tested for HIV (primary analysis). All individuals identified with an HIV indicator condition (secondary analysis).

    Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).

  15. Implementation science 3b: Effectiveness: Impact on disease stage at presentation

    Assessment of the impact of the HIV indicator condition-based testing approach on CD4 count at HIV diagnosis, measured as a continuous variable to assess shifts in stage at presentation. Primary analysis: Mean CD4 count at HIV diagnosis in the intervention phase vs. control phase (continuous variable). Secondary analysis: Distribution of CD4 counts at diagnosis (percentiles and quartiles) to evaluate changes in the proportion of late-stage diagnoses. Proportion of patients diagnosed with advanced HIV (CD4 \<200 cells/µL) in both phases. Proportion of patients diagnosed with late-stage HIV (CD4 \<350 cells/µL) in both phases. Proportion of patients diagnosed at higher CD4 thresholds (e.g., \>500 cells/µL) to assess shifts towards earlier diagnosis.

    Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).

  16. Implementation science 4a: Adoption of HIV Indicator Condition-based testing

    Hospital adoption rate (%): Proportion of participating hospitals that have adopted all core components of HIV indicator condition-based testing. as well as: Degree of adoption across the hospital (%): Proportion of hospital departments (inpatients, outpatients, SEH, IC) that are included in the surveillance of HIV indicator condition-based testing.

    Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).

  17. Implementation science 5a: Implementation - Fidelity to the implementation strategies

    This outcome assesses the degree to which the #aware.hiv Europe implementation strategies were delivered as intended across participating hospitals. Percentage of flagged potential HIV indicator conditions that were assessed by the HIV team (surveillance) Percentage of untested indicator conditions for which HIV testing advice was provided to physicians (feedback) Number of teaching sessions delivered compared to the intended frequency, with a minimum of one session every three months in the implementation phase (teaching). Number of stigma-reducing events organized, with a minimum requirement of one event in the implementation phase (stigma).

    Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year)

  18. Implementation science 5b: Implementation - Adaptation of the implementation strategies

    This outcome assesses the extent to which the #aware.hiv Europe implementation strategies were adapted to fit the local context while maintaining core components across participating hospitals. The number and type of modifications made to the implementation strategy at the hospital level will be assessed using qualitative data collected via a structured questionnaire. Responses will be categorized according to the key components of the implementation strategy: * Audit and Feedback * Teaching and Education * Enabling Environment (including stigma reduction) * Linkage to Prevention

    Time frame: This will be assessed every three months during the implementation phase, and every 6 months in the first year of the continuation phase..

  19. Implementation science 5c: Implementation - Acceptability and appropriateness of the implementation strategies

    This outcome assesses how acceptable and appropriate the #aware.hiv Europe implementation strategies are perceived by healthcare professionals authorised to request HIV tests, using questions embedded in the hospital-wide stigma questionnaire.

    Time frame: As part of the stigma questionnaire before and after the implementation phase.

  20. Cost-effectiveness

    Cost-effectiveness will be estimated by calculating the budget impact and Quality-Adjusted Life Years (QALYs) saved to define an Incremental Cost-Effectiveness Ratio (ICER).

    Time frame: The one-year implementation phase will be compared to the preceding control phase, and the continuation phase (second year) will be compared to both the implementation and control phases to assess cost-effectiveness.

  21. Epidemiological impact

    The epidemiological impact will be estimated by quantifying the number of earlier HIV diagnoses achieved through the intervention, and modelling the resulting reduction in the number of person-years spent living with undiagnosed HIV. In addition, the number of secondary HIV infections potentially averted due to earlier diagnosis and treatment initiation will be estimated. Estimate the reduction in average time from infection to diagnosis based on clinical data and literature. Calculate the total number of person-years with undiagnosed HIV prevented through earlier detection. Use published transmission rates for undiagnosed individuals to model the number of secondary infections averted. If available, incorporate local or national modelling tools (e.g., ECDC HIV Modelling Tool) to support these estimates.

    Time frame: The one-year implementation phase will be compared to the control phase, and the continuation phase (second year) will be compared to both preceding phases.

07

Study locations

27 of 28 sites recruiting
  • University Hospital Ghent
    Ghent, Belgium
    Not yet recruiting
  • European hospital of Marseille
    Marseille, 13003, France
    Recruiting
    • Christina Psomas, Dr. · Contactkcpsomas@gmail.com · +33 4 13 42 70 00
    • Christina Psomas, Dr. · Principal investigator
  • St. Joseph Krankenhaus Berlin Tempelhof
    Berlin, 12101, Germany
    Recruiting
    • Pascal Migaud, Dr. Med. · ContactPascal.Migaud@sjk.de · +493078825500
    • Pascal Migaud, Dr. Med. · Principal investigator
  • Charité Universitätsmedizin Berlin
    Berlin, 13353, Germany
    Recruiting
    • Christian Gaebler, Prof. Dr. Med. · Contactchristian.gaebler@charite.de · +49 30 45050
    • Christian Gaebler, Prof. Dr. med. · Principal investigator
  • Cologne University Hospital
    Cologne, 50937, Germany
    Recruiting
    • Jakob J. Malin, Priv.-Doz. Dr. · ContactJakob.Malin@uk-koeln.de · +492214780
    • Jakob J. Malin, Priv.-Doz. Dr. · Principal investigator
  • Klinikum der Technischen Universität München (TUM)
    München, 81675, Germany
    Recruiting
    • Florian Voit, Dr. med.sci. · Contactflorian.voit@mri.tum.de · +498941408274
    • Florian Voit, Dr. med. sci. · Principal investigator
  • Ospedale San Raffaele S.r.l
    Milan, Italy
    Recruiting
    • Silvia Nozza, Dr. · Contactnozza.silvia@hsr.it · +39 02 26431
    • Silvia Nozza, Dr. · Principal investigator
  • L'Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS
    Roma, 00149, Italy
    Recruiting
    • Valentina Mazzotta, Dr. · Contactvalentina.mazzotta@inmi.it · +390655170923
    • Valentina Mazzotta, Dr. · Principal investigator
  • Rijnstate ziekenhuis
    Arnhem, Netherlands
    Recruiting
    • Jet Gisolf, Dr. · Contactjgisolf@rijnstate.nl · 0880056735
    • Jet Gisolf, Dr. · Principal investigator
  • Stichting Catharina Ziekenhuis
    Eindhoven, 5623EJ, Netherlands
    Recruiting
  • University Medical Center Groningen
    Groningen, 9713GZ, Netherlands
    Recruiting
    • Wouter F.W. Bierman, Dr. · Contactw.f.w.bierman@umcg.nl · 050 361 6161
    • Wouter F.W. Bierman, Dr. · Principal investigator
  • Stichting Maasstad Ziekenhuis
    Rotterdam, 3079DZ, Netherlands
    Recruiting
  • Haga Ziekenhuis
    The Hague, Netherlands
    Recruiting
  • SPZZOZ Janów Lubelski
    Janów Lubelski, 23-300, Poland
    Recruiting
    • Tomasz Szumski, Dr. · Contacttommyszumski10@wp.pl · +48 15 843 63 61
    • Tomasz Szumski, Dr. · Principal investigator
  • Wojewodzki Szpital Zespolony
    Kielce, 25-736, Poland
    Recruiting
    • Dorota Zarębska-Michaluk, Dr. · Contactdorota1010@tlen.pl · +48 41 367 13 01
    • Dorota Zarębska-Michaluk, Dr. · Principal investigator
  • Państwowy Instytut Medyczny MSWiA w Warszawie
    Warsaw, 02-507, Poland
    Recruiting
  • Central Military Emergency University Hospital "Dr. Carol Davila"
    Bucharest, 010825, Romania
    Recruiting
    • Stefan Ion, Dr. · Contactdr.stefanion@gmail.com · +40 744 309 559
    • Ștefan Ion, Dr. · Principal investigator
  • Clinical Emergency Hospital "Prof. Dr. Agrippa Ionescu"
    Bucharest, 011356, Romania
    Recruiting
    • Valeriu Gheorghiță, MD. PhD · Contactsecretariat.agrippa@dcti.ro · +40377726145
    • Valeriu Gheorghiță, MD. PhD · Principal investigator
  • National Institute for Infectious Diseases "Prof. Dr. Matei Bals"
    Bucharest, 021105, Romania
    Recruiting
    • Oana Săndulescu, MD. PhD · Contactoana.sandulescu@umfcd.ro · +40723768779
    • Oana Săndulescu, MD. PhD · Principal investigator
  • Fundeni Clinical institute
    Bucharest, 022328, Romania
    Recruiting
    • Cristina Negulescu, Dr. · Contactsecretariat@icfundeni.ro · +4 021.317.21.94
    • Cristina Negulescu, Dr. · Principal investigator
  • Spitalul Universitar de Urgență București
    Bucharest, 050098, Romania
    Recruiting
    • Diana G. Iacob, Dr. · Contactsecretariat@suub.ro · (+40) 733 650 240
    • Diana G. Iacob, Dr. · Principal investigator
  • Hospital Universitario La Paz-Carlos III
    Madrid, 28029, Spain
    Recruiting
  • Infanta Leonor
    Madrid, Spain
    Recruiting
  • La Princesa
    Madrid, Spain
    Recruiting
  • Central city clinical hospital of Ivano-Frankivsk city council
    Ivano-Frankivsk, Ukraine
    Recruiting
    • Roman Fishchuk, Dr. · Contactfishchukroman@gmail.com · +380 95 103 1030
    • Roman Fishchuk, Dr. · Principal investigator
  • Lviv National Medical University
    Lviv, 79010, Ukraine
    Recruiting
    • Maryana Sluzhynska, Dr. · Contactmsluzhynska@gmail.com · +380 322 757 632
    • Maryana Sluzhynska, Dr. · Principal investigator
  • Buckinghamshire Healthcare NHS Trust
    Aylesbury, HP21 8AL, United Kingdom
    Recruiting
    • Angela Bailey, Dr. · Contactangela.bailey16@nhs.net · 01296 315000
    • Angela Bailey, Dr. · Principal investigator
  • Royal Free London
    London, NW3 2QG, United Kingdom
    Recruiting
    • Tristan Barber, MD. · Contactt.barber@nhs.net · +44 20 7794 0500
    • Tristan Barber, MD · Principal investigator
08

References and documents

Publications

  • Jordans CCE, Vliegenthart-Jongbloed K, Osbak KK, Hanssen JLJ, van Beek J, Vriesde M, van Holten N, Dorama W, van der Sluis D, de Steenwinkel J, van Kampen J, Verbon A, Roukens AHE, Rokx C. Implementing HIV teams sustainably improves HIV indicator condition testing rates in hospitals in the Netherlands: the #aware.hiv clinical trial. AIDS. 2025 Jul 1;39(8):995-1004. doi: 10.1097/QAD.0000000000004167. Epub 2025 Mar 18. PubMed 40053486 ↗
  • Jordans CCE, Vliegenthart-Jongbloed KJ, van Bruggen AW, van Holten N, van Beek JEA, Vriesde M, van der Sluis D, Verbon A, Roukens AHE, Stutterheim SE, Rokx C. Unmasking Individual and Institutional HIV Stigma in Hospitals: Perspectives of Dutch Healthcare Providers. AIDS Behav. 2024 Sep;28(9):3184-3195. doi: 10.1007/s10461-024-04404-0. Epub 2024 Jun 13. PubMed 38869755 ↗
  • Vliegenthart-Jongbloed KJ, Vasylyev M, Jordans CCE, Bernardino JI, Nozza S, Psomas CK, Voit F, Barber TJ, Skrzat-Klapaczynska A, Sandulescu O, Rokx C; #aware.hiv Europe Project. Systematic Review: Strategies for Improving HIV Testing and Detection Rates in European Hospitals. Microorganisms. 2024 Jan 25;12(2):254. doi: 10.3390/microorganisms12020254. PubMed 38399659 ↗

Related links

Individual participant data

Plan to share: No — While aggregated results may be published, the protocol does not support the sharing of individual-level data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2029, 42 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 42 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 28, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Apr 1, 2029
CompletionEst.
Feb 1, 2030
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06900829
Lead sponsor
Casper Rokx
Responsible party
Casper Rokx (Internist-infectiologist, Associate professor, Erasmus Medical Center) — Sponsor-investigator
First posted
Mar 28, 2025
Start date
Oct 1, 2025
Primary completion
Apr 1, 2029 (estimated)
Completion
Feb 1, 2030 (estimated)
Last update
Mar 12, 2026

Study contacts

Klaske J Vliegenthart-Jongbloed, Internist-Infectiologist, DTMH
Contact
k.vliegenthart-jongbloed@erasmusmc.nl
0031648382045
Marianne van Wingerden, Research nurse
Contact
aware.hiv@erasmusmc.nl
0031107040704
Casper Rokx, Infectiologist, associate prof
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion